12:00 AM
 | 
Aug 15, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Ontak denileukin diftitox: Phase III started

Eisai disclosed in its fiscal 1Q11 earnings ending June 30 that it began a U.S. Phase III trial to evaluate Ontak....

Read the full 85 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >